Galectin Therapeutics (NASDAQ:GALT) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $11.00 price objective on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2027 earnings at $1.25 EPS and FY2028 earnings at $3.39 EPS.

Separately, StockNews.com downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

Galectin Therapeutics Trading Up 0.7 %

Shares of GALT traded up $0.02 during midday trading on Friday, reaching $2.77. The stock had a trading volume of 219,074 shares, compared to its average volume of 145,910. Galectin Therapeutics has a one year low of $1.55 and a one year high of $4.27. The firm has a market cap of $172.52 million, a PE ratio of -3.51 and a beta of 0.62. The firm has a 50 day simple moving average of $2.69 and a 200-day simple moving average of $2.62.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). As a group, research analysts forecast that Galectin Therapeutics will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in GALT. Marshall Wace LLP acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at $43,000. Rhumbline Advisers bought a new position in shares of Galectin Therapeutics during the 2nd quarter worth approximately $44,000. Gladstone Institutional Advisory LLC bought a new position in Galectin Therapeutics during the third quarter worth $60,000. Barclays PLC grew its stake in shares of Galectin Therapeutics by 309.0% in the 3rd quarter. Barclays PLC now owns 28,587 shares of the company’s stock valued at $79,000 after buying an additional 21,598 shares during the period. Finally, Traynor Capital Management Inc. increased its position in Galectin Therapeutics by 23.5% in the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock valued at $97,000 after buying an additional 8,164 shares in the last quarter. Institutional investors own 11.68% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.